access intranet after hours circle-arrow apply blog caret circle arrow close closer look community outreach community outreach contact contact us down arrow facebook find a provider find a clinical trial find a provider find a researcher find faculty how to apply join leadership left arrow locations logo make a gift map location maximize minimize my chart my chart notification hp notification lp next nxt prev pay your bill play previous quality and safety quality and safety refer a patient request a speaker request appointment request an appointment request-an-appointment residents corner rss search search jobs Asset 65 submit a story idea symptom checker twitter youtube

Our Donors

MUSC Children's Hospital would not be the successful pediatric health care organization it is today without the generous support of so many individuals, groups and businesses. Through generous donations of time, funds, good and services our facility remains a thriving, growing and caring institution, built by and for our community.

We greatly appreciate the many philanthropists that are an integral part of our success. The opportunities for our hospital are endless and with your support we continue to grow into one of the best pediatric hospitals in the United States. We thank you for supporting the MUSC Children’s Hospital.

Endowed Chairs
Endowed Funds
Circle of Champions
Darby Legacy Society

Endowment Donors

Endowment Donors ensure that the MUSC Children's Hospital continues to be one of the best pediatric health care institutions in the United States. The generosity of endowment donors allows them to become a part of the healing tradition at the MUSC Children's Hospital. Endowment donors also make possible the advancements of new treatments and cures, compassionate caregivers, and a hospital with a child-friendly atmosphere.

Endowed Chairs

MUSC Children's Hospital and the Charles P. Darby Children's Research Institute have launched an ambitious initiative to increase the number of distinguished endowed chairs and directorships currently dedicated to the treatment and research of childhood diseases.

Recruitment and retention of top researchers and clinicians are the most important factors in building the reputation of an institution. Yet, there is a great deal of competition for outstanding faculty. In order to obtain and retain world-class leaders who not only achieve groundbreaking discoveries but also convey that knowledge to the next generation of physicians and researchers, it is essential that we are able to offer these leaders the recognition and funds to pursue their work. Endowed chairs and directorships are the most important tools we have to attract those individuals.

Endowed chairs are highly prized among scientists because they provide a stable source of research funding – a rare commodity in research. Also, conventionally funded researchers are often required to focus exclusively on a narrowly defined set of questions, whereas chair-holders are free to pursue unexpected lines of inquiry that might arise during their research. The freedom provided by chairs makes them highly attractive to researchers. Finally, both endowed chairs and directorships are tremendously prestigious honors, signifying that one has achieved distinction as a preeminent clinician or researcher. As such, the prospect of holding an endowed chair or a directorship is an extremely powerful inducement for a scientist to join our institution.

A minimum contribution of $1 million is required to endow a chair and establish a directorship. For the purposes of our discussion, the main distinction between the two positions is the chair’s status as an endowed fund. With an endowed fund, only the investment income may be used. By policy set forth by the MUSC Foundation (HSF) Board, only a portion of investment income is expended (currently 5%), so that the Foundation’s endowment funds will grow over time. The corpus is never invaded, thereby ensuring that the endowment will exist in perpetuity. However, with the directorship fund, the entire investment can be used as needed at the director’s discretion. While directorship funds lack guaranteed perpetuity, they do provide the faculty member holding the position with more flexibility and latitude to expand and develop programs.

The Jean and George W. Brumley, Jr. Endowed Chair in Neonatology

The Jean and George W. Brumley,Jr. M.D Endowed Chair in Neonatology will be used to support clinical, education, and research goals within the Department of Neonatology. The philosophy of our clinical enterprise is to improve care through a combination of multidisciplinary evidence-based practice, best practices, and quality & safety programs. Each of these is multidisciplinary. Funds would be used to support and expand these programs. In addition, this chair would foster the integration of research advances into clinical practice, through translational research and clinical programs which continue to monitor and analyze effectiveness of therapies as they are disseminated.

Finally, and most importantly, there are several projects pertaining to neonates under investigation in the Darby Children’s Research Institute, with a major emphasis on neonatal nutrition, pulmonary biochemistry, and preservation of neuro-developmental outcomes (“brain protection”). These interests include bench research and the translation of bench research into clinical care. The Jean and George W. Brumley Endowed Chair will be used to support and expand these programs, provide the resources to develop junior investigators into competitive researchers, and conduct new cutting edge research resulting in better treatments and possible cures.

The Sherman Financial Endowed Chair in Neurology
The Charles P. Darby Children’s Research Institute established The Sherman Financial Endowed Chair in neurosciences to honor the nationally-known scientific director Dr. Inderjit Singh, who has gained national prominence for his research on statins. This endowed chair will support the efforts of a distinguished physician who will bring the latest in pediatric neurological care to the state of South Carolina. This individual will work closely with Dr. Singh on the development of clinical trials and bridge the gap between laboratory developments and the patient’s treatment. Some of the areas of development include stroke, mental retardation, and spinal cord injury.

Distinguished Directorship in Oncology

While cancer is a terrible diagnosis at any age, it is devastating when it occurs in a child. Each year in the United States, approximately 12,400 children and adolescents are diagnosed with cancer. Approximately 2,300 young people die of cancer each year, making cancer the leading cause of death among people under the age of 20. At this point, not much is understood about the causes of childhood cancer.

Over the past 20 years or so, we have seen an increase in incidence of cancer among young people. However, we also have seen a dramatic increase in survival rates, thanks to the research, development and refinement of new treatments. Developing new therapies for treating all types of cancer is crucial. This directorship will support the efforts of a distinguished physician who will bring the latest in cancer care to the state of South Carolina.

Distinguished Directorship in Nephrology

Kidney disease is a big problem in South Carolina, striking one out of every eight citizens. An estimated 460,000 South Carolinians currently have chronic kidney disease.

Renal disease is a common disease in children. In the general population, slightly more than 30 people in every 100,000 develop kidney failure each year. In the pediatric population—age 19 and under—the annual rate is only 1 or 2 new cases in every 100,000 children. In other words, adults are about 20 times more likely to develop kidney failure than children. The risk increases steadily with age.

There is a clear and compelling need for accelerated research in this area, and we need to recruit and retain leaders who will be able to make an impact through their clinical work and research. Unfortunately, there is a severe shortage of pediatric nephrologists, due to the fact that only 15 of these specialists graduate from fellowship programs in the United States each year. Consequently, they are exceedingly difficult to recruit and retain. We have a desperate problem in this area and need to recruit and retain leaders who will be able to make an impact through their clinical work and research.

Endowed Funds

The Charles P. Darby Children’s Research Institute (DCRI) is the largest and most comprehensive pediatric research facility in the Carolinas. In the last five years, DCRI investigators have made more than 500 breakthroughs. These discoveries have resulted in new grant awards, new patents, new start-up companies, and a first-in-the-nation clinical trial to prevent cerebral palsy. The following are among the studies taking place at the Institute:

Congenital Heart Disease
Congenital heart disease (CHD) is the most common malformation in newborns. Current research efforts focus on repair and regeneration of the heart with novel compounds, including ACT1 which was discovered by one of our scientists, Dr. Gourdie. ACT1 promotes wound healing and clinical trials have started.

Cerebral Palsy

Congenital heart disease (CHD) is the most common malformation in newborns. Current research efforts focus on repair and regeneration of the heart with novel compounds, including ACT1 which was discovered by one of our scientists, Dr. Gourdie. ACT1 promotes wound healing and clinical trials have started.

Spinal Cord Injury

Accidental injury is the leading cause of death in children and Dr. Singh discovered that atorvastatin, commonly known as Lipitor, prevents the development of paralysis after traumatic injury.

Type I Diabetes

Drs. Key and Singh have shown that Lipitor dramatically protects insulin-producing cells in Type1 diabetes. Based on these findings, clinical trials are being conducted in children with diabetes and trials are planned for spinal cord injury.

Brain Tumors

Cancer is a leading cause of death and disability in children. Drs. Maria and Toole have developed a novel anti-cancer compound, hyaluronan oligomers (o-HA), that has been licensed to Halozyme Therapeutics, Inc. for further development and clinical trials. It is a sugar-like biologic treatment without toxicity or immunogenicity that ‘raises the bar’ for children with these tumors. 

Autism
The prevalence of autism is on the rise and our drug metabolism scientists are working with the Autism Program to better understand why some children respond to medications and others have significant side effects. They have shown that genetic mutations in brain drug transporters and metabolizing enzymes explain why some patients have major side effects at small doses. These findings are significant because they make possible genetic screening of patients before medications are started.

Vitamin D
Over the past five years, Drs. Hollis and Wagner in our Vitamin D group have made important discoveries about the functions of vitamin D. Their research has been critical to recent changes in Federal recommendations of daily requirements of vitamin D in children. The group is collaborating with others trying to understand and exploit the anti-inflammatory and anti-cancer effects of vitamin D.

Healthy Bones
In addition to the work on vitamin D, Dr. Reddy’s group found that a missing gene causing a neurologic disease, spinal muscular atrophy, also impaired normal bone formation. The Institute is making major advances in understanding ways to maintain a healthy skeleton, including a clinical trial of alendronate (Fosamax) for juvenile osteoporosis.

Targeted Inhibitors of Inflammation
The Institute houses some of the most accomplished experts on immunity in the world. The complement system is involved in inflammation in childhood arthritis, in states of decreased blood flow, in heart transplantation, in liver injury, in lupus, and in a variety of disorders of childhood including spinal cord injury and stroke. Drs. Tomlinson and Gilkeson have developed new complement inhibitors which are now being developed for treatment of childhood and adult inflammatory disorders.

Kidney Disease
The Renal Biology Program directed by Dr. Bell has made major advances in understanding how cilia, hair-like structures in the kidneys, cause cystic kidney disease. Importantly, they have identified compounds that could change the natural history of the genetic disease that affects so many children and adults.

For more information about the Charles P. Darby Children's Research Institute, please call Barbara Rivers at 843-792-6643 or e-mail riversb@musc.edu.

Circle of Champions

The Circle of Champions is a group of parents, businesses and other friends united by one mission: To ensure that young people in South Carolina have access to the world’s best medical care and treatment options, through MUSC Children’s Hospital.

Founded in 1987 and nurtured by philanthropic gifts from people like you, MUSC Children’s Hospital has grown into a regional leader in children’s health, providing young people throughout the entire state of South Carolina with the world’s most advanced diagnostic and patient services.

Champions help us:

  • Recruit new caregivers to the Children's Hospital and investigators to the Darby Children's Research Institute
  • Equip our facilities with the most advanced technologies
  • Conduct cutting-edge research to prevent, treat and cure childhood diseases and provide the best care possible

Circle of Champions Membership:

As a Circle of Champions member you can help build community support for MUSC Children’s Hospital while providing vital resources for the hospital and its research center, Charles P. Darby Children’s Research Institute.

By joining the Circle of Champions you will receive:

  • A personal tour of the MUSC Children’s Hospital and the Charles P. Darby Children’s Research Institute.
  • Invitations to special events where you will learn about exciting new programs and meet doctors, caregivers and other benefactors.
  • Opportunities to meet and learn from the world-class physicians and researchers you helped us recruit.
  • A subscription to Miracle Makers, a magazine for friends of the hospital.

Join the Circle of Champions:

To make a gift please call 843-792-6643 or toll-free at 800-810-MUSC or send your tax-deductible donation to:

MUSC Children’s Hospital
Circle of Champions
18 Bee Street
Charleston, SC 29425

Please make checks payable to the MUSC Foundation.

Darby Legacy Society

The Darby Legacy Society consists of people who have made a gift to the Children’s Hospital through their estate plans. Members of this honorary group have included us in their wills, charitable trusts, charitable annuities, life insurance policies or other planned gift arrangements.

With a planned gift, you commit to make the gift today, but the gift does not actually pass to the hospital until the end of your life. That way, you are able to make a larger contribution than would be possible during your lifetime.